Serum metabolic profiling of targeted bile acids reveals potentially novel biomarkers for primary biliary cholangitis and autoimmune hepatitis

BACKGROUND Primary biliary cholangitis (PBC) and autoimmune hepatitis (AIH) are two unexplained immune diseases. The golden standard for diagnosis of these diseases requires a liver biopsy. Liver biopsy is not widely accepted by patients because of its invasive nature, and atypical liver histology can confuse diagnosis. In view of the lack of effective diagnostic markers for PBC and AIH, combined with the increasingly mature metabolomics technologies, including full-contour metabolomics and target. AIM To determine non-invasive, reliable, and sensitive biochemical markers for the differential diagnosis of PBC and AIH. METHODS Serum samples from 54 patients with PBC, 26 patients with AIH and 30 healthy controls were analyzed by Ultra-high performance liquid chromatography-tandem mass spectrometry serum metabolomics. The metabolites and metabolic pathways were identified, and the metabolic changes, metabolic pathways and inter-group differences between PBC and AIH were analyzed. Fifteen kinds of target metabolites of bile acids (BAs) were quantitatively analyzed by SRM, and the differential metabolites related to the diagnosis of PBC were screened by receiver operating characteristic curve analysis. RESULTS We found the changes in the levels of amino acids, BAs, organic acids, phospholipids, choline, sugar, and sugar alcohols in patients with PBC and AIH. Furthermore, the SRM assay of BAs revealed the increased levels of chenodeoxycholic acid, lithocholic acid (LCA), taurolithocholic acid (TLCA), and LCA + TLCA in the PBC group compared with those in the AIH group. The levels of BAs may be used as biomarkers to differentiate PBC from AIH diseases. The levels of glycochenodeoxycholic acid, glycochenodeoxycholic sulfate, and taurodeoxycholic acid were gradually elevated with the increase of Child-Pugh class, which was correlated with the severity of disease. CONCLUSION The results demonstrated that the levels of BAs could serve as potential biomarkers for the early diagnosis and assessment of the severity of PBC and AIH.

[1]  Bangmao Wang,et al.  The Microbiome in Autoimmune Liver Diseases: Metagenomic and Metabolomic Changes , 2021, Frontiers in Physiology.

[2]  L. Trouw,et al.  The role of complement activation in autoimmune liver disease. , 2020, Autoimmunity reviews.

[3]  Peiyuan Yin,et al.  Serum metabolome and targeted bile acid profiling reveals potential novel biomarkers for drug-induced liver injury , 2019, Medicine.

[4]  Bo Li,et al.  Comprehensive Analysis of Serum and Fecal Bile Acid Profiles and Interaction with Gut Microbiota in Primary Biliary Cholangitis , 2019, Clinical Reviews in Allergy & Immunology.

[5]  Cheng-Hai Liu,et al.  Serum Metabolomics Analysis Reveals a Distinct Metabolic Profile of Patients with Primary Biliary Cholangitis , 2017, Scientific Reports.

[6]  Ren Yan,et al.  Alterations and correlations of the gut microbiome, metabolism and immunity in patients with primary biliary cirrhosis. , 2016, Environmental microbiology.

[7]  H. Jia,et al.  A serum metabolomic analysis for diagnosis and biomarker discovery of primary biliary cirrhosis and autoimmune hepatitis. , 2015, Hepatobiliary & pancreatic diseases international : HBPD INT.

[8]  Ying-mei Tang,et al.  Urine and serum metabolomic profiling reveals that bile acids and carnitine may be potential biomarkers of primary biliary cirrhosis , 2015, International journal of molecular medicine.

[9]  L. Davidovic,et al.  Metabolic Profiling and Phenotyping of Central Nervous System Diseases: Metabolites Bring Insights into Brain Dysfunctions , 2015, Journal of Neuroimmune Pharmacology.

[10]  Y. Ohashi,et al.  Serum metabolomic profile and potential biomarkers for severity of fibrosis in nonalcoholic fatty liver disease , 2013, Journal of Gastroenterology.

[11]  Shelly C. Lu,et al.  Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression. , 2012, Journal of proteome research.

[12]  F. Gonzalez,et al.  Lithocholic acid disrupts phospholipid and sphingolipid homeostasis leading to cholestasis in mice , 2011, Hepatology.

[13]  S. Ekins,et al.  Evolution of promiscuous nuclear hormone receptors: LXR, FXR, VDR, PXR, and CAR , 2011, Molecular and Cellular Endocrinology.

[14]  G. Gores,et al.  American association for the study of liver diseases endpoints conference: Design and endpoints for clinical trials in primary biliary cirrhosis , 2010, Hepatology.

[15]  Xin Lu,et al.  A metabonomic study of hepatitis B-induced liver cirrhosis and hepatocellular carcinoma by using RP-LC and HILIC coupled with mass spectrometry. , 2009, Molecular bioSystems.

[16]  O. Briz,et al.  Bile-acid-induced cell injury and protection. , 2009, World journal of gastroenterology.

[17]  J. Marin,et al.  Bile acids: chemistry, physiology, and pathophysiology. , 2009, World journal of gastroenterology.

[18]  John T. Wei,et al.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression , 2009, Nature.

[19]  Wei Li,et al.  Bile acids metabonomic study on the CCl4- and alpha-naphthylisothiocyanate-induced animal models: quantitative analysis of 22 bile acids by ultraperformance liquid chromatography-mass spectrometry. , 2008, Chemical research in toxicology.

[20]  G. Kullak-Ublick,et al.  The role of FXR in disorders of bile acid homeostasis. , 2008, Physiology.

[21]  Nathan Blow,et al.  Metabolomics: Biochemistry's new look , 2008, Nature.

[22]  I. Mackay,et al.  Autoimmune liver serology: current diagnostic and clinical challenges. , 2008, World journal of gastroenterology.

[23]  Peiyuan Yin,et al.  Metabonomics study of intestinal fistulas based on ultraperformance liquid chromatography coupled with Q-TOF mass spectrometry (UPLC/Q-TOF MS). , 2006, Journal of proteome research.

[24]  J. Lindon,et al.  Pharmaco-metabonomic phenotyping and personalized drug treatment , 2006, Nature.

[25]  A. Hofmann.  Detoxification of Lithocholic Acid, A Toxic Bile Acid: Relevance to Drug Hepatotoxicity , 2004, Drug metabolism reviews.

[26]  A. Leikin-Frenkel,et al.  Prevention of diet‐induced fatty liver in experimental animals by the oral administration of a fatty acid bile acid conjugate (FABAC) , 2003, Hepatology.

[27]  F. Gonzalez,et al.  Protective Role of Hydroxysteroid Sulfotransferase in Lithocholic Acid-induced Liver Toxicity* , 2003, The Journal of Biological Chemistry.

[28]  F. Gonzalez,et al.  Regulation of P450 genes by liver-enriched transcription factors and nuclear receptors. , 2003, Biochimica et biophysica acta.

[29]  J. Goto,et al.  A monoclonal antibody-based enzyme-linked immunosorbent assay of glycolithocholic acid sulfate in human urine for liver function test , 2002, Steroids.

[30]  N. Javitt.  Cholesterol, hydroxycholesterols, and bile acids. , 2002, Biochemical and biophysical research communications.

[31]  E. Goetzl.  Pleiotypic mechanisms of cellular responses to biologically active lysophospholipids. , 2001, Prostaglandins & other lipid mediators.

[32]  M. Straka,et al.  Role of Oxidant Stress in the Permeability Transition Induced in Rat Hepatic Mitochondria by Hydrophobic Bile Acids , 2001, Pediatric Research.

[33]  M. Manns,et al.  International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. , 1999, Journal of hepatology.

[34]  U. Spengler,et al.  Hepatic levels of bile acids in end-stage chronic cholestatic liver disease. , 1996, Clinica chimica acta; international journal of clinical chemistry.

[35]  D. Billington,et al.  Effects of bile salts on the plasma membranes of isolated rat hepatocytes. , 1980, The Biochemical journal.

[36]  R. Coppel,et al.  New insights to the immunopathology and autoimmune responses in primary biliary cirrhosis. , 2006, Cellular immunology.

[37]  K. Setchell,et al.  Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei. , 1997, Gastroenterology.

[38]  D. Alvaro,et al.  Bile acid-induced liver toxicity: relation to the hydrophobic-hydrophilic balance of bile acids. , 1986, Medical hypotheses.